<DOC>
	<DOCNO>NCT02913105</DOCNO>
	<brief_summary>The purpose present study assess effect LMB763 respect safety , tolerability , marker liver inflammation patient NASH</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Efficacy LMB763 Patients With NASH</brief_title>
	<detailed_description />
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Male/female patient , 18 year old Written inform consent Presence NASH histologic evidence ( liver biopsy ) elevate alanine aminotransferase ( ALT ) , OR phenotypic diagnosis NASH base elevate ALT , BMI diagnosis Type 2 diabetes mellitus Current use obeticholic acid ( OCA ) New initiation GLP1 agonists liraglutide , exenatide , lixisenatide , albiglutide dulaglutide within 3 month screen Pregnant nursing ( lactate ) woman Women childbearing potential , unless use highly effective method contraception dose 5 day stop study medication Current history significant alcohol consumption period 3 consecutive month within 1 year prior screen Clinical evidence hepatic decompensation severe liver impairment Previous diagnosis form chronic liver disease Uncontrolled diabetes mellitus History current diagnosis ECG abnormalities Patients contraindication MRI image</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Non-alcoholic Steatohepatitis</keyword>
	<keyword>NASH</keyword>
	<keyword>Fatty liver disease</keyword>
</DOC>